The role of bevacizumab as first-line therapy for colon cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 9, 2005, Pages 43-47

  Marshall, John ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER GROWTH; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOSIS;

EID: 30544439661     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.06.003     Document Type: Conference Paper

References (15)

1. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncol 2 2001 533 543
2. D. Hanahan, R. Weinberg The hallmarks of cancer Cell 100 2000 57 70
3. Y. Takahashi, S.L. Tucker, Y. Kitadai Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer Arch Surg 132 1997 541 546
4. R. Jain Normalizing tumor vasculature with anti-angiogenic therapy; a new paradigm for combination therapy Nat Med 7 2001 987 989
5. N. Fernando, H. Hurwitz Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer Semin Oncol 30 2003 39 50
6. Avastin [package insert]. South San Francisco, CA, Genentech, Inc.
7. F. Kabbinavar, H. Hurwitz, L. Fehrenbacher Phase II, randomized trial omparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
8. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
9. E.E. Hedrick, H. Hurwitz, S. Sarkar Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). 2004 American Society of Clinical Oncology Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 suppl 2004 14s (abstr 3517)
10. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
11. Giantonio BJ, Catalano PJ, Meropol NJ,, et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An updated interim analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2004 (abstr 241)
12. A phase III trial of modified FOLFOX6 versus CAPOX, with bevacizumab (NSC-704865) or placebo, as first-line therapy in patients with previously untreated advanced colorectal cancer. Available at: http://www.swog.org/ visitors/ViewProtocolDetails.asp?ProtocolID=1929 (accessed October 19, 2004)
13. Phase III randomized study of oxaliplatin and bevacizumab (Avastin) with fluorouracil and leucovorin calcium or capecitabine in patients with advanced colorectal cancer. Available at: http://www.cancer.gov/clinicaltrials/ view_clinicaltrials.aspx?version=healthprofessional&cdrid= 304771&protocolsearchid=908619 (accessed October 19, 2004)
14. Capecitabine in combination with oxaliplatin (XELOX) with or without bevacizumab versus fluorouracil and leucovorin calcium or capecitabine in patients with advanced colorectal cancer. Available at: http://www. clinicaltrials.gov/ct/show/NCT00069095?order=1 (accessed October 19, 2004)
15. Phase II randomized study of bevacizumab and cetuximab with or without irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. Available at: www.clinicaltrials.gov/ct/show/NCT00077298?order=4 (accessed October 19, 2004)